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The Effect of Peripheral Percutaneous Transluminal Angioplasty on
Quality of Life in Patients with Intermittent Claudication
K. Cassar1, P. Bachoo2 and J. Brittenden1
1Department of Vascular Surgery, University of Aberdeen and 2Vascular Unit,
Aberdeen Royal Infirmary, Foresterhill, Aberdeen, U.K.
Background and Objective: intermittent claudication is associated with a significant reduction in quality of life.
Treatment of claudicants aims to reduce mortality from cardio- and cerebro-vascular events and to improve quality of
life. Quality of life assessment should be used to guide and evaluate treatment in this group of patients. Peripheral
percutaneous transluminal angioplasty (PTA) is now widely used in the treatment of intermittent claudication. The aim
of this review is to examine the effect of PTA on quality of life (QOL) in patients with intermittent claudication.
Methods: a review was conducted of prospective clinical trials assessing the effect of peripheral PTA on QOL. Publications
were retrieved by searching Medline and PreMedline, EMBASE, the Cochrane Central Register of Controlled Trials, the
Cochrane Database of systematic reviews, AMED and CINAHL. The reference lists of the relevant publications were also
searched.
Results: seven prospective studies (10 publications) on the effect of PTA on QOL in claudicants were identified. Several
different questionnaires were used to measure quality of life (Nottingham Health Profiile, SF-36, EuroQol) none of which
were disease specific. All the studies showed some improvement in QOL after PTA at follow-up periods of between 6 weeks
and 24 months, except for one which showed some improvement at 6 months but not at 24 months.
Conclusions: despite the fact that studies on the effect of PTA on QOL in claudicants have used generic QOL
questionnaires which are relatively insensitive, the findings suggest that PTA may result in some improvement in QOL
in these patients, although level I evidence to support this is lacking. The availability of disease-specific questionnaires
should enable a more accurate assessment of PTA on QOL in these patients.
Key Words: Angioplasty; Intermittent claudication; Quality of life.
Introduction
Intermittent claudication is a common problem affect-
ing between 1.7 and 10%1±4 the population over
50 years of age, with a higher prevalence in men.5
The major risk of these patients is increased mortality,
mainly from cardiovascular causes, compared to
age matched controls such that 30% are dead within
5 years.6 Twenty-five to thirty percent of patients
experience significant deterioration in their lower
limb symptoms over 5 years but only 1±2% per year
require amputation.7 As a result of this, intermittent
claudication is often perceived to be a benign condi-
tion with respect to the lower limbs. Patients are often
treated conservatively because clinicians feel that the
risks of revascularisation are not justified.8 Over the
last decade percutaneous transluminal angioplasty
(PTA) has been more widely used in the treatment of
intermittent claudication mainly because of its low
associated morbidity and mortality.9±11
Patients with intermittent claudication have been
shown to have a significantly diminished quality of
life compared to age- and sex-matched controls in
several studies.12±16 Claudication is a subjective
phenomenon and surgeons' assessment of patients'
quality of life has been shown to be poor.17 The aim
of treatment in this group of patients is primarily to
reduce the risk of mortality and morbidity from
cardio- and cerebro-vascular events and secondly to
improve symptoms and quality of life.
Traditional endpoints of PTA include ankle-brachial
pressure indices, maximal walking distance, or vessel
patency on duplex scanning. Little correlation has
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been shown to exist between these modalities.18 The
Trans-Atlantic Inter-Society Consensus (TASC) stated
that if QOL could be accurately assessed, then it
should be the ideal primary endpoint.19 To aid the
decision-making process, information should be avail-
able not only on the degree of impairment in quality of
life but also on the expected improvement in quality
of life obtained by different treatment options.
The aim of this review is to examine the effect of
PTA on quality of life in patients with intermittent
claudication.
Methods
The Medline and PreMedline database from 1966 to
2002 was searched using the keywords `` intermittent
claudication'', `` angioplasty'' and `` quality of life'',
with the Boolean operator `` and''. The search was
restricted to titles and abstracts. Criteria for inclusion
of studies in this systematic review were prospective
studies of the effect of PTA on quality of life (QOL) in
patients with intermittent claudication. Further
searches were performed using the same keywords
in EMBASE (1980±2003), the Cochrane Central
Register of Controlled Trials, the Cochrane
Database of systematic reviews, AMED (Allied and
Complementary Medicine: 1985±2003), and CINAHL
(1982±2003). References from the relevant articles
were also searched. When more than one article was
available from a single study, an attempt was made
to extract the information required from all relevant
publications.
Studies investigating the effect of
PTA on QOL
Seven prospective studies investigating the effect of
PTA on QOL in patients with intermittent claudication
were identified,20±29 three of which reported twice
at different follow-up intervals21±26 giving a total of
10 publications (Table 1).
Randomised controlled trials
Of the seven studies, two were randomised controlled
trials20±22 although only one has compared PTA to
conservative treatment.21,22 Whyman and colleagues
reported their results of a randomised controlled trial
of PTA for intermittent claudication at 6 months21 and
2 years22 post-PTA. The patients in the PTA group
received the same medical treatment (low dose
aspirin plus advice on smoking and exercise) as the
conservative treatment group besides their endovas-
cular procedure. None of the patients took part in a
supervised exercise programme. A modified Notting-
ham Health Profile (NHP)30 was administered to all
patients at baseline, at 3, 6 and 24 months' follow-up.
The NHP enquires about six modalities of quality of
life: pain, mobility, sleep, emotion, energy and isola-
tion. Other outcome measures such as treadmill exer-
cise test, ankle-brachial pressure index, and Duplex
ultrasound were also measured in this study.
Only 62 patients out of 600 claudicants assessed
were found to have lesions suitable for angioplasty.
Thirty were randomised to PTA and 32 to the control
group. This was a mixed group with either femoral
stenoses, femoral occlusions or iliac stenoses. Hunt
and colleagues,30 who developed the NHP, recom-
mended that the weights for each item are trans-
formed to yield scores from 0 to 100, but the
investigators in this study used a simpler scoring
system which only counts the number of affirmative
responses in each section. There were no differences at
baseline but at 6 months the PTA group had a lower
pain score than the control group. There were
no identifiable differences however between the two
groups in the other five quality of life modalities. At
2 year follow up there was no difference between the
two groups in any of the six quality of life modalities
leading the investigators to conclude that PTA did not
result in a significant improvement in QOL compared
to controls. These findings imply that the initial
improvement in QOL seen with PTA in the short-
term is not maintained.
These findings however are in conflict with those of
the Dutch Iliac Stent Trial Study Group.15 In a multi-
centre randomised controlled trial exploring the QOL
in patients with iliac disease undergoing primary
stent placement or primary angioplasty followed
by selective stent placement, Bosch and colleagues
showed that at 2 years both forms of treatment
resulted in a significant improvement in QOL com-
pared to baseline values. RAND 36-Item Health
Survey, which is equivalent to the Medical Outcomes
Study Short Form 36, was used in this study which
included 254 patients with iliac stenoses or occlusions.
The RAND 36 includes eight health dimensions: phys-
ical functioning, physical role functioning, emotional
role functioning, social functioning, bodily pain, gen-
eral health perception, mental health and vitality. For
each dimension responses to items are summed and
scores are converted to a 0 to 100 scale. Euro-Qol-5D,
which is a generic utility measurement instrument,
was also used. The EuroQol measures five dimensions
of health: mobility, self care, usual activities, pain/
discomfort and anxiety/depression.31 At 2 years the
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scores of all RAND-36 dimensions were significantly
higher than before treatment. Unfortunately both
groups randomised received some type of treatment
and there was no control group that was treated
conservatively.
Prospective observational studies
The other five studies, reported between 1995 and
200023±29 were all prospective observational studies
with sample size varying from 19 to 117. Chetter
and colleagues23,24 reported on a mixed group of
117 patients with either femoral, iliac or combined
iliofemoral disease undergoing PTA. Short form
36 (SF36) and EuroQol were used to measure QOL at
baseline, and at 1, 3, 6 and 12 months following inter-
vention. SF-36, like RAND-36, is a generic question-
naire containing 36 questions covering the same eight
health domains. For each dimension, question scores
are coded, summed and transformed onto a scale
from 0 (worst possible score) to 100 (best possible
score). The U.K. version of the SF36 was used in this
study. Chetter and colleagues found that PTA resulted
in an immediate and lasting improvement in the QOL
of claudicants. Unilateral claudicants undergoing
PTA to a solitary iliac lesion demonstrated the most
marked improvement in QOL, and at 12 months post
PTA their QOL approached that of a healthy age-
matched population. On the other hand iliac PTA
above a significantly disease SFA did not result in
any significant improvement in QOL.
Currie and colleagues27 also used the SF-36 to study
the effect of PTA on QOL in 74 patients with femoral,
iliac, popliteal or mixed disease. They found that
physical function, pain scores, general health percep-
tion as well as mental health improved significantly in
this group of patients group at 3 months after PTA.
In another study,28 42 patients with intermittent
claudication treated with PTA were found to have
a significant improvement in their quality of life
6 months after PTA. No information is available in
the paper as to the site or severity of disease in the
patients with intermittent claudication treated with
angioplasty. The NHP was used to evaluate quality
of life in this study. The QOL measure after PTA for
particular domains such as sleep, social isolation, paid
employment and family relationships approached
that of 102 healthy controls from a local population
study. Improvement was also seen in the QOL meas-
ure for pain, emotional reactions, physical mobility,
energy, housework, hobbies, holidays, sex and social
life but this did not reach the same level as in the
healthy controls.
Cook and colleagues25,26 followed up 29 patients
with intermittent claudication who underwent suc-
cessful PTA of the femoropopliteal or iliac arteries
for 6 weeks, and 24 of these for 1 year. EuroQol scores
were used to assess quality of life at baseline and at
6 weeks and 1 year after PTA. Following successful
PTA the EuroQol score, perceived health state,
mobility, usual activities, pain and discomfort and
mental state were all significantly improved. These
improvements were maintained at 1 year although
perceived health state deteriorated slightly.
Pell and colleagues16 used the SF-36 questionnaire
to assess QOL in 201 claudicants. 19 underwent PTA,
19 underwent surgical reconstruction and the rest
were managed conservatively. At 6 months patients
who had undergone PTA or arterial reconstruction
showed significant improvements in quality of life,
while those treated conservatively showed deteriora-
tion in all aspects of quality of life.
Discussion
All the seven studies reporting on the effect of PTA on
QOL in claudicants found an improvement in QOL
that was observed soon after PTA and that was main-
tained for up to 2 years, except for the study by
Whyman and colleagues who found that the initial
improvement in QOL at six months was not main-
tained at 2 years. No randomised controlled trial has
been conducted that follows patients' QOL for longer
periods of time. This is unfortunate as it is essential to
know the longterm outcome especially because of the
natural history of intermittent claudication.
The low risk of amputation in patients with inter-
mittent claudication combined with the significant
incidence of coronary artery disease has led to recom-
mendations to treat these patients conservatively with
regards to their lower limb symptoms.32,33 However
this ignores the considerable impairment in quality of
life associated with the condition. Patients with inter-
mittent claudication have a quality of life comparable
to patients with osteoarthritis or rheumatoid arthritis
affecting the hip or knee joint34 or patients with
coronary heart disease.35 Clinicians are poor at assess-
ing the impact of disease on patients' perception of
quality of life particularly in patients with intermittent
claudication17,36±37 and it is therefore important for
QOL measures to be used not only in the research
setting but also in the clinical setting to aid the deci-
sion-making process. In assessing outcome QOL
should also be considered besides the traditional
efficacy/safety model.38 Information on the improve-
ment in QOL of different treatment options should be
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available to clinicians in order to allow them to inform
and advise patients effectively.
Medical outcomes measured from the patients' pers-
pective should have a more important role in deter-
mining who should receive therapy than more
traditional outcome measures such as ankle-brachial
pressure indices, treadmill walking distance, and
patency rates.39 Brevetti and colleagues40 have argued
that QOL evaluation appears to be the most appropri-
ate tool to evaluate the net result of treatment in
patients with intermittent claudication. This concurs
with the recommendation of the Trans-Atlantic Inter-
Society Consensus statement19 that QOL is the ideal
primary endpoint in intermittent claudication espe-
cially as there is poor correlation between traditional
outcome measures such as exercise capacity assessed
by treadmill or improvement in ankle pressure with
quality of life.19,27,41
However, in order to assess QOL, a sensitive and
reliable instrument is required. In the studies reported
above various instruments have been used to assess
QOL but all of these were generic questionnaires such
as the SF-36, RAND-36, and the NHP. Three of the
studies have used EuroQOL which is a utility meas-
urement instrument.15,23,25 The major disadvantage of
using generic health questionnaires is that these tend
to be less sensitive and often require large sample
sizes to demonstrate statistically significant differ-
ences due to the large standard deviations of health
profiles. The NHP, used by Whyman et al.21 in the only
RCT comparing PTA with conservative treatment, is
particularly insensitive. The authors themselves con-
ceded that in patients with intermittent claudication
`` patients' quality of life has to be markedly impaired
before a difference can be established''. A simplified
method for scoring the questionnaire was used rather
than the actual scoring recommended by the develo-
pers of the NHP. Besides, their sample size was small
(30 PTA vs 32 controls). The combination of an
inappropriate health profile questionnaire and a
small sample size casts doubt on their conclusion
that there is no improvement in QOL in patients
with IC after PTA at 2 years. Indeed their findings
are not supported by any of the other six studies on
the effect of PTA on QOL. It might be argued that the
lack of QOL improvement at 2 years reflects the dura-
bility of PTA. However, Bosch et al.15 did show
improved QOL at 2 years after iliac PTA and/or
stenting.
The SF-36, another generic questionnaire, was
found to be more valid and reliable than the NHP
for use in the vascular setting.42 Four of the seven
studies, comprising a total of 464 patients, used SF-36
or a modification of it (RAND-36) to assess quality of
life and all of these found an improvement in QOL
after PTA.
Disease specific instruments would have the added
advantage of demonstrating more responsiveness
between patients depending on disease severity, or
within patients before and after therapy43 than the
generic questionnaires. For this reason various
attempts have been made to develop a disease-specific
questionnaire for use in intermittent claudication. The
Walking Impairment Questionnaire (WIQ) was one of
the first disease-specific health profile instruments to
be developed for peripheral vascular disease.44 This
15-item questionnaire examines four dimensions of
peripheral vascular disease: claudication-specific
pain, walking speed, walking distance and stair climb-
ing. The VascuQol is another questionnaire designed
to measure quality of life in patients with lower limb
ischaemia45 but its ability to detect small but impor-
tant changes in QOL impairment in claudicants after
treatment is questionable as it is not specific to clau-
dication. Silvestro and colleagues46 have developed
a disease-specific questionnaire for use in intermittent
claudication in Italian and another questionnaire, the
CLAU-S has undergone validation in English, French,
German and Flemish.47 More recently Chong and
colleagues48 have developed the Intermittent Claudi-
cation Questionnaire (ICQ) which has been shown to
be a practical, reliable, valid and responsive measure
of patient health-related quality of life in intermittent
claudication. This questionnaire was initially piloted
in 20 patients and then administered to 124 stable
claudicants. The instrument is scored on a scale from
0 to 100, where 0 is the best possible and 100 the worst
possible health state. Responsiveness of the question-
naire to changes in health was assessed in 60 patients
treated conservatively and 40 treated with angio-
plasty. The patients undergoing PTA showed a signifi-
cant improvement in their ICQ score at 3 months
while those treated conservatively showed no
improvement. The availability of sensitive disease-
specific questionnaires should make the assessment
of QOL in this group of patients more accurate.
Patency results after angioplasty are better for iliac
lesions rather than femoropopliteal lesions. This sug-
gests that improvement in QOL may also be different
when different sites are treated. Unfortunately five of
the seven studies had patients with different sites and
or severity of disease treated and in one study28 no
information is given as to the site or severity of the
disease. In future, studies on the effect of angioplasty
on QOL should analyse results from patients with
different sites of disease separately.
Unfortunately, despite the fact that PTA has been
used for almost 40 years49 and despite its widespread
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use in the treatment of intermittent claudication,11
there is still a lack of level I evidence to show that
PTA in IC results in significantly better QOL than
conservative or exercise treatment. This is particularly
important given the natural history of intermittent
claudication which may result in improvement in QOL
without endovascular intervention. Disease-specific
questionnaires are ideally suited to demonstrate the
value of different treatment options for patients with
intermittent claudication and should be used in ran-
domised controlled trials to establish the treatment of
choice in intermittent claudication, thus guiding
appropriate resource allocation. The weight of the
evidence available to date however suggests that
PTA in claudicants is associated with a significant
improvement in quality of life which appears to be
maintained at least until 24 months after the procedure.
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